MetaADEDB 2.0 @ LMMD
sivelestat
(BTGNGJJLZOIYID-UHFFFAOYSA-N)
Structure
SMILES
OC(=O)CNC(=O)c1ccccc1NS(=O)(=O)c1ccc(cc1)OC(=O)C(C)(C)C
Type(s)
Investigational
Molecular Formula:
C20H22N2O7S
Molecular Weight:
434.463
Log P:
3.7980
Hydrogen Bond Acceptor:
9
Hydrogen Bond Donor:
3
TPSA:
147.25
CAS Number(s):
127373-66-4
Synonym(s)
1.
sivelestat
2.
N-(2-(4-(2,2-dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid
3.
ONO 5046
4.
ONO-5046
5.
Ono-EI-600
External Link(s)
MeSHC069195
PubChem Compound107706
BindingDB166439
50084637
ChEBI135704
CHEMBLCHEMBL76688
DrugBankDB12863
DrugCentral2452
IUPHAR/BPS Guide to PHARMACOLOGY6441
KEGGdr:D03788
Therapeutic Target DatabaseD0FT4R
ZINC21298097
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Activated partial thromboplastin time abnormalOFFSIDES
2Acute myocardial infarctionOFFSIDES
3Adrenal cortex necrosisOFFSIDES
4Adverse eventOFFSIDES
5Alanine Aminotransferase IncreasedOFFSIDES
6Antithrombin III decreasedOFFSIDES
7Aspiration PneumoniaOFFSIDES
8Bilirubin conjugated increasedOFFSIDES
9Blood GlucoseOFFSIDES
10Blood albumin decreasedOFFSIDES
11Blood amylase increasedOFFSIDES
12Blood cholinesterase decreasedOFFSIDES
13Blood creatine phosphokinase increasedOFFSIDES
14Blood creatinine increasedOFFSIDES
15Blood lactate dehydrogenase increasedOFFSIDES
16Blood urea increasedOFFSIDES
17Blood uric acid decreasedOFFSIDES
18Brain natriuretic peptide increasedOFFSIDES
19Cardiovascular insufficiencyOFFSIDES
20CheilitisOFFSIDES
21Concomitant disease progressionOFFSIDES
22CystOFFSIDES
23Depressed Level of ConsciousnessOFFSIDES
24DiabetesOFFSIDES
25Disease ProgressionOFFSIDES
26Disseminated Intravascular CoagulationOFFSIDES
27Eosinophilic myocarditisOFFSIDES
28ErythemaOFFSIDES
29Failure to anastomoseOFFSIDES
30Gastrointestinal hypomotilityOFFSIDES
31Gastrointestinal infectionOFFSIDES
32General physical health deteriorationOFFSIDES
33Graft dysfunctionOFFSIDES
34Heparin-induced thrombocytopeniaOFFSIDES
35Leukopenia neonatalOFFSIDES
36Lymphocyte count decreasedOFFSIDES
37MalabsorptionOFFSIDES
38Malignant neoplasm progressionOFFSIDES
39Mechanical ventilationOFFSIDES
40Multi-organ disorderOFFSIDES
41Muscle necrosisOFFSIDES
42Neutrophil count decreasedOFFSIDES
43Plasminogen decreasedOFFSIDES
44Pneumocystis jiroveci pneumoniaOFFSIDES
45PneumothoraxOFFSIDES
46Postoperative abscessOFFSIDES
47Postoperative infectionOFFSIDES
48Protein total decreasedOFFSIDES
49Prothrombin time abnormalOFFSIDES
50Respiratory Distress Syndrome, Adult16930140CTD
51Respiratory FailureOFFSIDES
52Septic ShockOFFSIDES
53Skin necrosisOFFSIDES
54Sputum retentionOFFSIDES
55Subcutaneous EmphysemaOFFSIDES
56Unresponsive to pain stimuliOFFSIDES
57Ventricular FibrillationOFFSIDES
58Vitamin K DeficiencyOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.